We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Announces Initiative to Boost Fentanyl’s Safety

FDA Announces Initiative to Boost Fentanyl’s Safety

April 4, 2019

FDA Commissioner Scott Gottlieb announced new steps the agency is taking to tighten safety requirements for transmucosal immediate-release fentanyl (TIRF) products.

Gottlieb said the agency is sending notices to manufacturers of TIRF medicines—a class of products indicated to manage breakthrough pain in cancer patients who are routinely taking other opioid pain managements—regarding agency changes to the risk evaluation and mitigation strategy (REMS) for TIRF products. 

“It’s clear more needs to be done to better ensure the safe use of these medicines, mitigate their risks and assure appropriate prescribing,” he said.

One REMS change requires prescribers to record a patient’s opioid tolerance alongside each prescription of a TIRF drug for outpatient use. In addition, TIRF medicines dispensed for outpatient use must now be accompanied by evidence of safe use conditions—including “concurrent documentation of opioid tolerance.”

View today's stories

Pharmaceuticals Postmarket Safety

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Acquires -Acquired

    Amgen to Buy Five Prime Therapeutics for $1.9 Billion

  • abbott-logo.gif

    Abbott Secures EUA for COVID-19 Combination Test

  • Eli Lilly logo

    Eli Lilly’s COVID-19 Antibody and Combo Therapy Gets Positive EMA Recommendation

  • AdaptiveBiotechnologies_Logo.png

    FDA Grants EUA for Adaptive Biotechnologies’ T Cell COVID-19 Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing